Addex Therapeutics Ltd (ADXN.SW)
CHF 0.05
(-3.21%)
CHF 0.05
(-3.21%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.49 Million CHF | 3.78% |
| 2022 | 3.36 Million CHF | -39.95% |
| 2021 | 5.61 Million CHF | 0.69% |
| 2020 | 5.57 Million CHF | -25.76% |
| 2019 | 7.5 Million CHF | 152.42% |
| 2018 | 2.97 Million CHF | 72.79% |
| 2017 | 1.72 Million CHF | 17.5% |
| 2016 | 1.46 Million CHF | 19.49% |
| 2015 | 1.22 Million CHF | -25.89% |
| 2014 | 1.65 Million CHF | -42.06% |
| 2013 | 2.85 Million CHF | -47.59% |
| 2012 | 5.44 Million CHF | -44.33% |
| 2011 | 9.78 Million CHF | -0.91% |
| 2010 | 9.86 Million CHF | -10.05% |
| 2009 | 10.97 Million CHF | -17.73% |
| 2008 | 13.33 Million CHF | 43.92% |
| 2007 | 9.26 Million CHF | 127.45% |
| 2006 | 4.07 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.04 Million CHF | -77.79% |
| 2024 Q1 | 4.7 Million CHF | 34.68% |
| 2023 Q3 | 2.19 Million CHF | -23.63% |
| 2023 Q4 | 3.49 Million CHF | 59.39% |
| 2023 FY | 3.49 Million CHF | 3.78% |
| 2023 Q2 | 2.87 Million CHF | -10.89% |
| 2023 Q1 | 3.22 Million CHF | -4.33% |
| 2022 FY | 3.36 Million CHF | -39.95% |
| 2022 Q4 | 3.36 Million CHF | -21.46% |
| 2022 Q3 | 4.28 Million CHF | -5.08% |
| 2022 Q1 | 4.72 Million CHF | -15.77% |
| 2022 Q2 | 4.51 Million CHF | -4.37% |
| 2021 Q2 | 5.1 Million CHF | -17.27% |
| 2021 FY | 5.61 Million CHF | 0.69% |
| 2021 Q1 | 6.17 Million CHF | 10.83% |
| 2021 Q4 | 5.61 Million CHF | 18.89% |
| 2021 Q3 | 4.71 Million CHF | -7.63% |
| 2020 FY | 5.57 Million CHF | -25.76% |
| 2020 Q1 | 7.09 Million CHF | -5.47% |
| 2020 Q3 | 3.9 Million CHF | -10.2% |
| 2020 Q4 | 5.57 Million CHF | 42.78% |
| 2020 Q2 | 4.34 Million CHF | -38.74% |
| 2019 Q1 | - CHF | -100.0% |
| 2019 Q2 | 5.69 Million CHF | 0.0% |
| 2019 Q4 | 7.5 Million CHF | 0.0% |
| 2019 FY | 7.5 Million CHF | 152.42% |
| 2018 Q2 | 2.59 Million CHF | 10.34% |
| 2018 Q1 | 2.35 Million CHF | 36.77% |
| 2018 Q3 | 2.33 Million CHF | -10.13% |
| 2018 FY | 2.97 Million CHF | 72.79% |
| 2018 Q4 | 2.97 Million CHF | 27.39% |
| 2017 FY | 1.72 Million CHF | 17.5% |
| 2017 Q4 | 1.72 Million CHF | 16.51% |
| 2017 Q3 | 1.47 Million CHF | 0.6% |
| 2017 Q2 | 1.46 Million CHF | 18.34% |
| 2017 Q1 | 1.24 Million CHF | -15.29% |
| 2016 Q2 | 1.42 Million CHF | 37.08% |
| 2016 Q4 | 1.46 Million CHF | 17.16% |
| 2016 Q3 | 1.24 Million CHF | -12.03% |
| 2016 Q1 | 1.03 Million CHF | -15.42% |
| 2016 FY | 1.46 Million CHF | 19.49% |
| 2015 Q4 | 1.22 Million CHF | 19.0% |
| 2015 FY | 1.22 Million CHF | -25.89% |
| 2015 Q2 | 1.16 Million CHF | 19.08% |
| 2015 Q1 | 977.53 Thousand CHF | -40.88% |
| 2015 Q3 | 1.02 Million CHF | -11.53% |
| 2014 Q2 | 2.36 Million CHF | 30.18% |
| 2014 Q4 | 1.65 Million CHF | 9.58% |
| 2014 Q3 | 1.5 Million CHF | -36.08% |
| 2014 FY | 1.65 Million CHF | -42.06% |
| 2014 Q1 | 1.81 Million CHF | -36.45% |
| 2013 Q2 | 6.56 Million CHF | 0.0% |
| 2013 Q1 | 6.56 Million CHF | 20.59% |
| 2013 FY | 2.85 Million CHF | -47.59% |
| 2013 Q4 | 2.85 Million CHF | 20.75% |
| 2013 Q3 | 2.36 Million CHF | -64.01% |
| 2012 Q4 | 5.44 Million CHF | 16.94% |
| 2012 Q3 | 4.65 Million CHF | -46.27% |
| 2012 FY | 5.44 Million CHF | -44.33% |
| 2012 Q2 | 8.66 Million CHF | 0.0% |
| 2011 Q4 | 9.78 Million CHF | 0.0% |
| 2011 FY | 9.78 Million CHF | -0.91% |
| 2011 Q2 | 9.72 Million CHF | 0.0% |
| 2010 Q2 | 7.71 Million CHF | 0.0% |
| 2010 Q4 | 9.86 Million CHF | 0.0% |
| 2010 FY | 9.86 Million CHF | -10.05% |
| 2009 FY | 10.97 Million CHF | -17.73% |
| 2009 Q4 | 10.97 Million CHF | 0.0% |
| 2008 FY | 13.33 Million CHF | 43.92% |
| 2007 FY | 9.26 Million CHF | 127.45% |
| 2006 FY | 4.07 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BB Biotech AG | 304.9 Million CHF | 98.853% |
| Basilea Pharmaceutica AG | 183.29 Million CHF | 98.092% |
| Evolva Holding SA | 4.27 Million CHF | 18.224% |
| Idorsia Ltd | 1.46 Billion CHF | 99.762% |
| Kuros Biosciences AG | 19.19 Million CHF | 81.784% |
| Molecular Partners AG | 21.92 Million CHF | 84.051% |
| Relief Therapeutics Holding AG | 24.16 Million CHF | 85.529% |
| Santhera Pharmaceuticals Holding AG | 49.68 Million CHF | 92.963% |